Shots:

• The 1st patient has been dosed in a P-III registrational trial to evaluate the efficacy & safety of Ivonescimab (PD-1/VEGF bi-specific Ab) + CT vs PBO + CT in 320 patients with LA or metastatic nsq. NSCLC with EGFR mutation failed after EGFR-TKI treatment
• The 1EPs of the study is PFS as assessed by IRRC. In the early clinical studies in Australia & China, Ivonescimab showed good safety & tolerability for multiple types of lung cancer, including NSCLC & SCLC with good anti-tumor effects
• Additionally, Ivonescimab also has the effect of stimulating antitumor immune responses & inhibiting tumor angiogenesis. The company is planning to initiate the P-III trial of Ivonescimab for SCLC

Ref: PR Newswire | Image: South China Morning Post